Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG CLASS:

Immunomodulator

DRUG CLASS:

Immunomodulator

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Related drugs:

‹

thymalfasin (0)

chlorogenic acid (0)

dendritic cell activation therapy (0)

minocycline (0)

hydroxychloroquine (7)

quaratusugene ozeplasmid (3)

SQZ-AAC-HPV (1)

HLA-matched donor mononuclear enriched leukocytes (0)

rimiducid activated rivogenlecleucel (0)

coprelotamab (0)

GSK2302024A (0)

MVA-BN-HER2 (0)

nelipepimut-S (0)

engineered donor allograft cell therapy (0)

parvovirus H-1 (0)

FT1050+FT4145 programmed mPB (0)

allodepleted T-cell immunotherapeutics (0)

TAEK-VAC-HerBy vaccine (0)

Undisclosed CISH inactivated TIL (0)

alpha-tocopheroloxyacetic acid (0)

thymalfasin (0)

chlorogenic acid (0)

dendritic cell activation therapy (0)

minocycline (0)

›

No biomarker	Melanoma	No biomarker	Melanoma	nivolumab + CMP-001 Sensitive: B - Late Trials nivolumab + CMP-001 Sensitive : B	nivolumab + CMP-001 Sensitive: B - Late Trials nivolumab + CMP-001 Sensitive : B
No biomarker	Melanoma	No biomarker	Melanoma	pembrolizumab + CMP-001 Sensitive: B - Late Trials pembrolizumab + CMP-001 Sensitive : B	pembrolizumab + CMP-001 Sensitive: B - Late Trials pembrolizumab + CMP-001 Sensitive : B
No biomarker	Non Small Cell Lung Cancer	No biomarker	Non Small Cell Lung Cancer	pembrolizumab + quaratusugene ozeplasmid Sensitive: B - Late Trials pembrolizumab + quaratusugene ozeplasmid Sensitive : B	pembrolizumab + quaratusugene ozeplasmid Sensitive: B - Late Trials pembrolizumab + quaratusugene ozeplasmid Sensitive : B
No biomarker	Small Cell Lung Cancer	No biomarker	Small Cell Lung Cancer	atezolizumab + quaratusugene ozeplasmid Sensitive: B - Late Trials atezolizumab + quaratusugene ozeplasmid Sensitive : B	atezolizumab + quaratusugene ozeplasmid Sensitive: B - Late Trials atezolizumab + quaratusugene ozeplasmid Sensitive : B
No biomarker	Prostate Cancer	No biomarker	Prostate Cancer	SV-102 Sensitive: B - Late Trials SV-102 Sensitive : B	SV-102 Sensitive: B - Late Trials SV-102 Sensitive : B
HLA-A*02	Solid Tumor	HLA-A*02	Solid Tumor	SQZ-AAC-HPV Sensitive: C2 – Inclusion Criteria SQZ-AAC-HPV Sensitive : C2	SQZ-AAC-HPV Sensitive: C2 – Inclusion Criteria SQZ-AAC-HPV Sensitive : C2
C1As	Multiple Myeloma	C1As	Multiple Myeloma	Proteasome inhibitor + Immunomodulator Resistant: C3 – Early Trials Proteasome inhibitor + Immunomodulator Resistant : C3	Proteasome inhibitor + Immunomodulator Resistant: C3 – Early Trials Proteasome inhibitor + Immunomodulator Resistant : C3
Chr del(17p)	Multiple Myeloma	Chr del(17p)	Multiple Myeloma	Proteasome inhibitor + Immunomodulator Resistant: C3 – Early Trials Proteasome inhibitor + Immunomodulator Resistant : C3	Proteasome inhibitor + Immunomodulator Resistant: C3 – Early Trials Proteasome inhibitor + Immunomodulator Resistant : C3
Chr t(4;14)	Multiple Myeloma	Chr t(4;14)	Multiple Myeloma	Proteasome inhibitor + Immunomodulator Sensitive: C3 – Early Trials Proteasome inhibitor + Immunomodulator Sensitive : C3	Proteasome inhibitor + Immunomodulator Sensitive: C3 – Early Trials Proteasome inhibitor + Immunomodulator Sensitive : C3
Chr t(14;16)	Multiple Myeloma	Chr t(14;16)	Multiple Myeloma	Proteasome inhibitor + Immunomodulator Sensitive: C3 – Early Trials Proteasome inhibitor + Immunomodulator Sensitive : C3	Proteasome inhibitor + Immunomodulator Sensitive: C3 – Early Trials Proteasome inhibitor + Immunomodulator Sensitive : C3
Chr t(14;20)	Multiple Myeloma	Chr t(14;20)	Multiple Myeloma	Proteasome inhibitor + Immunomodulator Sensitive: C3 – Early Trials Proteasome inhibitor + Immunomodulator Sensitive : C3	Proteasome inhibitor + Immunomodulator Sensitive: C3 – Early Trials Proteasome inhibitor + Immunomodulator Sensitive : C3
B2M elevation	Multiple Myeloma	B2M elevation	Multiple Myeloma	Immunomodulator Resistant: C3 – Early Trials Immunomodulator Resistant : C3	Immunomodulator Resistant: C3 – Early Trials Immunomodulator Resistant : C3